Ultragenyx Pharmaceutical Inc.
Simbol: RARE
NASDAQ
43.01
USDPrețul de piață astăzi
-5.9104
Raportul P/E
0.0654
Raportul PEG
3.54B
MRK Cap
- 0.00%
Randament DIV
Ultragenyx Pharmaceutical Inc. (RARE) Situații financiare
Bilanț
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2271.64 | 777.1 | 896.7 | 999.1 | |||||||||||||
balance-sheet.row.short-term-investments | 1482.9 | 363.6 | 614.8 | 432.6 | |||||||||||||
balance-sheet.row.net-receivables | 323.63 | 73.4 | 40.4 | 28.4 | |||||||||||||
balance-sheet.row.inventory | 129.93 | 34 | 26.8 | 16.2 | |||||||||||||
balance-sheet.row.other-current-assets | -638.48 | -777.1 | 68.9 | -187.2 | |||||||||||||
balance-sheet.row.total-current-assets | 2554.45 | 732.2 | 883.9 | 856.6 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 1207.13 | 290.6 | 285.7 | 176.2 | |||||||||||||
balance-sheet.row.goodwill | 177.62 | 44.4 | 44.4 | 44.4 | |||||||||||||
balance-sheet.row.intangible-assets | 646.86 | 166.3 | 160.1 | 130.8 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 824.48 | 210.7 | 204.5 | 175.2 | |||||||||||||
balance-sheet.row.long-term-investments | 436.17 | 199.9 | 154.5 | 293.9 | |||||||||||||
balance-sheet.row.tax-assets | 80.98 | 6 | 6.1 | 8.9 | |||||||||||||
balance-sheet.row.other-non-current-assets | 244.34 | 51.7 | 10.7 | 11.6 | |||||||||||||
balance-sheet.row.total-non-current-assets | 2793.09 | 758.8 | 661.5 | 665.8 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 5347.54 | 1491 | 1545.4 | 1522.4 | |||||||||||||
balance-sheet.row.account-payables | 158.56 | 42.1 | 43.3 | 17.1 | |||||||||||||
balance-sheet.row.short-term-debt | 91.02 | 12.6 | 11.8 | 11.1 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-debt-total | 928.7 | 30.6 | 19.8 | 30.9 | |||||||||||||
Deferred Revenue Non Current | 1736.75 | 862.3 | 0 | 1.5 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 123.45 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 410.65 | 29.2 | 204.7 | 145.6 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 3746.75 | 935.2 | 931.7 | 418.5 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 108.94 | 43.2 | 31.6 | 42 | |||||||||||||
balance-sheet.row.total-liab | 4771.12 | 1215.6 | 1193 | 599.8 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0.31 | 0.1 | 0.1 | 0.1 | |||||||||||||
balance-sheet.row.retained-earnings | -13315.3 | -3387.7 | -2781 | -2073.6 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -1.79 | 0.6 | -6.6 | -1.4 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 13893.21 | 3662.3 | 3140 | 2997.5 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 576.42 | 275.4 | 352.5 | 922.6 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 5347.54 | 1491 | 1545.4 | 1522.4 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-equity | 576.42 | 275.4 | 352.5 | 922.6 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 5347.54 | - | - | - | |||||||||||||
Total Investments | 1852.69 | 563.5 | 620.3 | 726.5 | |||||||||||||
balance-sheet.row.total-debt | 1013.14 | 43.2 | 31.6 | 42 | |||||||||||||
balance-sheet.row.net-debt | 506.37 | -170.4 | -101.4 | -265.6 |
Situația fluxurilor de numerar
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -613.35 | -606.6 | -707.4 | -454 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 29.61 | 26 | 18.2 | 13.2 | |||||||||||||
cash-flows.row.deferred-income-tax | -143.91 | -1.6 | -1.6 | 48.7 | |||||||||||||
cash-flows.row.stock-based-compensation | 140.2 | 135.2 | 130.4 | 105 | |||||||||||||
cash-flows.row.change-in-working-capital | -32.76 | -15.1 | 60.2 | -63.2 | |||||||||||||
cash-flows.row.account-receivables | -45.18 | -22.8 | -12.1 | -5.4 | |||||||||||||
cash-flows.row.inventory | -9.2 | -6.9 | -9.7 | -3.1 | |||||||||||||
cash-flows.row.account-payables | -0.41 | 2.4 | 87.4 | 2.8 | |||||||||||||
cash-flows.row.other-working-capital | 22.04 | 12.2 | -5.4 | -57.5 | |||||||||||||
cash-flows.row.other-non-cash-items | 228.72 | -12.7 | 119.8 | 11.7 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -508.67 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -34.94 | -46.8 | -146.1 | -73.1 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | -2.5 | -75 | 0 | |||||||||||||
cash-flows.row.purchases-of-investments | -486.29 | -526.4 | -614.7 | -1012.2 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 675.52 | 746.2 | 545.1 | 890.9 | |||||||||||||
cash-flows.row.other-investing-activites | -0.66 | -2.5 | -0.8 | -0.9 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 151.13 | 168 | -291.7 | -195.4 | |||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -490.9 | 0 | |||||||||||||
cash-flows.row.common-stock-issued | 354.26 | 379.8 | 10.8 | 78.9 | |||||||||||||
cash-flows.row.common-stock-repurchased | -0.06 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 34.55 | 8.4 | 981.3 | 39.6 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 388.81 | 388.1 | 501.2 | 118.6 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.43 | 0.5 | -1.1 | -1.2 | |||||||||||||
cash-flows.row.net-change-in-cash | 34.89 | 85.6 | -172 | -416.7 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 524.23 | 219.4 | 137.6 | 309.6 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 489.34 | 133.8 | 309.6 | 726.3 | |||||||||||||
cash-flows.row.operating-cash-flow | -508.67 | -474.8 | -380.5 | -338.7 | |||||||||||||
cash-flows.row.capital-expenditure | -34.94 | -46.8 | -146.1 | -73.1 | |||||||||||||
cash-flows.row.free-cash-flow | -543.61 | -521.6 | -526.6 | -411.8 |
Rândul din contul de profit și pierdere
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 442.59 | 434.2 | 363.3 | 351.4 | |||||||||||||
income-statement-row.row.cost-of-revenue | 59.33 | 45.2 | 28.3 | 16 | |||||||||||||
income-statement-row.row.gross-profit | 383.26 | 389 | 335 | 335.4 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 652.39 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 5.24 | -0.3 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.operating-expenses | 963.71 | 958.2 | 983.9 | 717.1 | |||||||||||||
income-statement-row.row.cost-and-expenses | 1023.04 | 1003.5 | 1012.2 | 733.1 | |||||||||||||
income-statement-row.row.interest-income | 29.22 | 26.7 | 11.1 | 1.9 | |||||||||||||
income-statement-row.row.interest-expense | 34.52 | 66 | 43 | 29.4 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -7.69 | -39.3 | -52.8 | -71.2 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 5.24 | -0.3 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.total-operating-expenses | -7.69 | -39.3 | -52.8 | -71.2 | |||||||||||||
income-statement-row.row.interest-expense | 34.52 | 66 | 43 | 29.4 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 27.61 | 26 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.ebitda-caps | -538.27 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -580.45 | -569.2 | -648.9 | -381.7 | |||||||||||||
income-statement-row.row.income-before-tax | -615.22 | -608.5 | -701.7 | -453 | |||||||||||||
income-statement-row.row.income-tax-expense | -1.86 | -1.8 | 5.7 | 1 | |||||||||||||
income-statement-row.row.net-income | -613.35 | -606.6 | -707.4 | -454 |
Întrebări frecvente
Ce este Ultragenyx Pharmaceutical Inc. (RARE) totalul activelor?
Ultragenyx Pharmaceutical Inc. (RARE) activele totale sunt 1491013000.000.
Care este venitul anual al întreprinderii?
Venitul anual este 236225000.000.
Care este marja de profit a întreprinderii?
Marja de profit a firmei este 0.866.
Care este fluxul de numerar liber al întreprinderii?
Fluxul de numerar liber este -6.450.
Care este marja de profit net a întreprinderii?
Marja profitului net este -1.386.
Care este venitul total al întreprinderii?
Venitul total este -1.311.
Care este Ultragenyx Pharmaceutical Inc. (RARE) profitul net (venitul net)?
Profitul net (venitul net) este -606639000.000.
Care este datoria totală a firmei?
Datoria totală este 43169000.000.
Care este numărul cheltuielilor de exploatare?
Cheltuielile de exploatare sunt 958248000.000.
Care este cifra de numerar a firmei?
Numerarul întreprinderii este 118554000.000.